Summary Nerve growth factor (NGF) administration to athymic mice with transplanted human bromocriptine-resistant prolactinoma, results in the expression of dopamine D-2 receptors in the tumour and restores sensitivity to subsequent treatment with bromocriptine, which then produces normalisation of plasma prolactin and tumour regression. Sequential administration of NGF and bromocriptine thus may be a promising therapy for patients refractory to bromocriptine.
Prolactin (PRL)-secreting pituitary adenomas are the most frequent neoplasm in the human pituitary and range in size from small microadenomas, i.e. tumours smaller than 1 cm in maximal diameter, to large extrasellar macroadenomas with signs of local invasiveness (Davis et al., 1990; Cunnah and Besser, 1991) . The symptoms of prolactinomas are mostly related to hyperprolactinaemia, but local symptoms, particularly headache, visual field defects and, more rarely, symptoms of cavernous sinus compression may occur when adenomas are large (Davis et al., 1990; Cunnah and Besser, 1991) .
The turning point in the management of PRL-secreting tumours was the discovery that they express D-2 receptors for dopamine (DA), the physiological inhibitor of PRL secretion (Wood et al., 1991) . This finding led to the development of the D-2 DA receptor agonist bromocriptine as the most effective pharmacological tool for therapy of prolactinomas (Cunnah and Besser, 1991; Wood et al., 1991) .
This therapy, however, is not invariably effective; 10-15% of patients are, in fact, non-responders and require pituitary surgery or external irradiation (Cunnah and Besser, 1991; Wood et al., 1991) . However, these are rarely successful in patients with extrasellar and/or invasive tumours (Schlechte et al., 1986) . Management of such non-responding patients thus remains a therapeutical challenge.
The major biochemical defect contributing to DA agonist resistance in prolactinomas is decreased density of D-2 receptors (Pellegrini et al., 1989) . In a recent study with human prolactinomas we found that the tumours clinically resistant to bromocriptine do not express D-2 receptors for DA (Missale et al., 1993) . However, these tumours do express receptors for nerve growth factor (NGF), a neurotrophic protein that promotes growth, differentiation and survival of specific populations of neurons (Levi-Montalcini, 1987) and that also exerts differentiating effects on cells of endocrine origin (Missale et al., 1994 15 ± 1 mm3, the mice were divided into four groups. Two groups were treated with saline (n = 12) and two groups with NGF (1 jigg-' body weight, i.v.; n = 12) once a day for 5 consecutive days. Fifteen days after the last NGF administration one subgroup of controls (n = 6) and one subgroup of NGF-treated mice (n = 6) were injected with bromocriptine to determine plasma PRL levels. Tumour size was measured before and after NGF administration during a 40 day followup period. Figure 1 shows the sizes of the transplanted tumours in saline-and NGF-treated mice at the end of the follow-up. Bromocriptine did not modify tumour growth in salinetreated mice (Figure 2b) . However, the drug recovered its full activity when injected into mice previously treated with NGF. As a result of bromocriptine administration, the tumour size progressively decreased, completely regressing within 11 days (Figure 2b ). Tumours did not reappear after bromocriptine therapy was discontinued (Figures lc and 2b ).
Mice transplanted with prolactinomas had higher plasma PRL levels than normal animals. Analysis of blood samples obtained immediately before and 2 days after beginning bromocriptine administration revealed bromocriptine-induced normalisation of PRL levels in NGF-treated animals (650 ±52ngml-' before bromocriptine and 195±15ngml-' after bromocriptine administration (Petty et al., 1994) .
Therefore, sequential therapy with NGF and bromocriptine appears to be a potential and promising alternative to neurosurgical intervention for patients with DA-resistant prolactinomas.
